Clinical trial assesses microRNA-122's potential as a biomarker during lifestyle interventions in steatotic liver disease, suggesting new avenues for treatment evaluation.
Objective Steatotic liver disease (SLD) is a prevalent chronic liver disease for which lifestyle intervention remains the first-line treatment. However, reliable biomarkers that reflect treatment responsiveness are limited. MicroRNA-122 (miR-122) is a liver-specific microRNA involved in hepatic lipid metabolism and injury. However, its clinical significance during lifestyle intervention has not yet been fully elucidated.
No takes yet. Share an insight, caveat, or question.
Eriksson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: